|
Sign In to gain access to subscriptions and/or personal tools.
|
Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression
M J Hohol
Multiple Sclerosis Unit of the Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA, Neurology, Room 4077, Queen Wing, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada
E J Orav
Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA
H L Weiner
Multiple Sclerosis Unit of the Center for Neurologic Diseases, Division of Neurology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clinical assessment of outcome in Multiple Sclerosis (MS) patients is problematic since the disease can affect different aspects of the central nervous system and follow a variable course. Recently, we developed Disease Steps, a simple approach for evaluating disease progression. Previously, we found that Disease Steps was easy to use, had uniformly distributed scores and low inter-rater variability. Our current objective was to test the long-term use of Disease Steps together with the most widely utilized clinical outcome measure in MS, the Expanded Disability Status Scale (EDSS) in assessing clinical progression. Over 4 years, 804 patients were classified using both EDSS and Disease Steps. Each patient was assessed at least twice. Follow-up results included annual status and time-to-event analysis examining median staying times within a level of Disease Steps or EDSS. We found that the two scales behaved similarly and correlated strongly with each other. For both Disease Steps and EDSS, patients with milder levels of disability and relapsing-remitting disease demonstrated a higher likelihood of changing scores over time and shorter median staying times compared to more disabled, chronic progressive patients. These findings have important implications for patient selection in clinical trials and for the design of future measurements of clinical outcome in MS. Furthermore, Disease Steps may serve as a simple, practical tool for the nonspecialty neurologist to follow patients over time and serve as a guide in therapeutic decision making. Our findings further document the general progressive nature of MS when a large cohort is followed in an MS specialty clinic over time.
Key Words: multiple sclerosis • clinical scale • disability
Multiple Sclerosis, Vol. 5, No. 5,
349-354 (1999)
DOI: 10.1177/135245859900500508
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. A. Marrie, G. Cutter, T. Tyry, and T. Vollmer
A cross-sectional study of bone health in multiple sclerosis
Neurology,
October 27, 2009;
73(17):
1394 - 1398.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Marrie, R. Horwitz, G. Cutter, T. Tyry, D. Campagnolo, and T. Vollmer
Comorbidity delays diagnosis and increases disability at diagnosis in MS
Neurology,
January 13, 2009;
72(2):
117 - 124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Marrie, R Horwitz, G Cutter, T Tyry, D Campagnolo, and T Vollmer
Comorbidity, socioeconomic status and multiple sclerosis
Multiple Sclerosis,
September 1, 2008;
14(8):
1091 - 1098.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Venken, N. Hellings, T. Broekmans, K. Hensen, J.-L. Rummens, and P. Stinissen
Natural Naive CD4+CD25+CD127low Regulatory T Cell (Treg) Development and Function Are Disturbed in Multiple Sclerosis Patients: Recovery of Memory Treg Homeostasis during Disease Progression
J. Immunol.,
May 1, 2008;
180(9):
6411 - 6420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Marrie and M. Goldman
Validity of performance scales for disability assessment in multiple sclerosis
Multiple Sclerosis,
November 1, 2007;
13(9):
1176 - 1182.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Marrie, G. Cutter, T. Tyry, T. Vollmer, and D. Campagnolo
Disparities in the management of multiple sclerosis-related bladder symptoms
Neurology,
June 5, 2007;
68(23):
1971 - 1978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-L. Sayao, V. Devonshire, and H. Tremlett
Longitudinal follow-up of "benign" multiple sclerosis at 20 years
Neurology,
February 13, 2007;
68(7):
496 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Marrie, G. Cutter, T. Tyry, T. Vollmer, and D. Campagnolo
Does multiple sclerosis-associated disability differ between races?
Neurology,
April 25, 2006;
66(8):
1235 - 1240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Shinto, V Yadav, C Morris, J A Lapidus, A Senders, and D Bourdette
Demographic and health-related factors associated with complementary and alternative medicine (CAM) use in multiple sclerosis
Multiple Sclerosis,
February 1, 2006;
12(1):
94 - 100.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Marrie, G. Cutter, T. Tyry, O. Hadjimichael, D. Campagnolo, and T. Vollmer
Changes in the ascertainment of multiple sclerosis
Neurology,
October 11, 2005;
65(7):
1066 - 1070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E L J Hoogervorst, M J Eikelenboom, B M J Uitdehaag, and C H Polman
One year changes in disability in multiple sclerosis: neurological examination compared with patient self report
J. Neurol. Neurosurg. Psychiatry,
April 1, 2003;
74(4):
439 - 442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H L Weiner and J A Cohen
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Multiple Sclerosis,
April 1, 2002;
8(2):
142 - 154.
[Abstract]
[PDF]
|
|
|
|
|
